Tax Reform in This Election Year: It's Not Likely
Which Credit Card Rewards Does the IRS Care About?
Ted Allrich is the founder of The Online Investor and author of the just-released book: Comfort Zone Investing: Build Wealth And Sleep Well At Night. In this weekly column, he'll offer advice to investors who are just getting started.
The last two columns described my experience with two biotech stocks. One was bad: Hollis-Eden Pharmaceuticals (NASDAQ: HEPH). One was good: Dendreon Corp. (NASDAQ: DNDN). (Please note that I am not recommending you buy or sell either of these.) Here's what I learned from the experience of losing a large amount of money, then gaining some of it back.
First, I got greedy. As they say on the Street, bulls and bears make money, pigs get slaughtered. I over-leveraged my position in HEPH because I got carried away with the science. I thought the stock was a sure winner. With all the indications coming from Washington that the company qualified for a contract, it just seemed impossible to lose. So I put way too much money on one stock, thinking this was a sure thing. But it wasn't. Without a contract, the company had no other revenues.
Goldman Earnings Sink After Buffett Dividend
Johnson & Johnson's Income Falls 23%
Burberry Shares Leap on Sales Update
